Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Autografting

Autologous stem cell transplantation is safe and feasible in elderly patients with multiple myeloma

Bone Marrow Transplantation volume 39, pages 279–283 (2007)Cite this article

Abstract

Several clinical trials have shown the superiority of autologous stem cell transplantation over conventional dose therapy for patients with multiple myeloma. This treatment, however, is limited to younger patients (<65 years) owing to concerns about toxicity and treatment-related mortality (TRM) in older patients. We treated 26 elderly myeloma patients (>70 years), who received a preparative regimen of melphalan 200 mg/m2 (19 patients), melphalan 180 mg/m2 (six patients) or melphalan 140 mg/m2 (one patient). Twenty-two of the 26 patients were alive after a median follow-up of 25 months (range=8–74). Responses (complete+partial response) were seen in 20 patients (77%), five (19%) of which were complete responses. Median PFS was 24 months, whereas median OS has not been reached. Cumulative incidence of 100-day TRM was 0%. Three-year PFS and OS were 39% (range=16–61) and 65% (range=35–83), respectively. A low serum albumin (<3.5 g/dl) was associated with a shorter PFS (P=0.02). Patients with relapsed disease at transplant, and an interval of >12 months between diagnosis and autotransplant, had a shorter OS (P=0.0004 and 0.04). HDT and autologous transplant is safe and feasible in elderly myeloma patients.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Hari P, Pasquini MC, Vesole DH . Cure of multiple myeloma – more hype, less reality. Bone Marrow Transplant 2006; 37: 1–18.

    Article  CAS  Google Scholar 

  2. Caldera H, Giralt S . Stem cell transplantation for multiple myeloma: current status and future directions. Curr Hematol Rep 2004; 3: 249–256.

    PubMed  Google Scholar 

  3. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF et al. Autologous bone marrow transplantation versus conventional chemotherapy in multiple myeloma. N Engl J Med 1996; 335: 9197.

    Article  Google Scholar 

  4. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K et al. Medical Research Council Adult Leukaemia Working Party. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875–1883.

    Article  CAS  Google Scholar 

  5. Fermand JP, Katsahian S, Divine M, Leblond V, Dreyfus F, Macro M et al. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55–65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol 2005; 23: 9227–9233.

    Article  CAS  Google Scholar 

  6. Blade J, Rosinol L, Sureda A, Ribera JM, Diaz-Mediavilla J, Garcia-Larana J et al. Programa para el Estudio de la Terapeutica en Hemopatia Maligna (PETHEMA). High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood 2005; 106: 3755–3759.

    Article  CAS  Google Scholar 

  7. Barlogie B, Kyle RA, Anderson KC, Greipp PR, Lazarus HM, Hurd DD et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol 2006; 24: 929–936.

    Article  CAS  Google Scholar 

  8. Lahuerta JJ, Martinez-Lopez J, Grande C, Blade J, de la Serna J, Alegre A et al. Conditioning regimens in autologous stem cell transplantation for multiple myeloma: a comparative study of efficacy and toxicity from the Spanish Registry for Transplantation in Multiple Myeloma. Br J Haematol 2000; 109: 138–147.

    Article  CAS  Google Scholar 

  9. Manoharan A . Gentle yet effective treatment for elderly patients with refractory or relapsing multiple myeloma. Am J Hematol 2000; 65: 81–82.

    Article  CAS  Google Scholar 

  10. Siegel DS, Desikan KR, Mehta J, Singhal S, Fassas A, Munshi N et al. Age is not a prognostic variable with autotransplants for multiple myeloma. Blood 1999; 93: 51–54.

    CAS  PubMed  Google Scholar 

  11. Badros A, Barlogie B, Siegel E, Morris C, Desikan R, Zangari M et al. Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years. Br J Haematol 2001; 114: 600–607.

    Article  CAS  Google Scholar 

  12. Moreau P, Facon T, Attal M, Hulin C, Michallet M, Maloisel F et al. Intergroupe Francophone du Myelome Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140l mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood 2002; 99: 731–735.

    Article  CAS  Google Scholar 

  13. Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated with high-dose therapy and haemopoetic stem cell transplantation. Br J Haematol 1998; 102: 1115–1123.

    Article  CAS  Google Scholar 

  14. Donato ML, Feasel AM, Weber DM, Prieto VG, Giralt SA, Champlin RE et al. Scleromyxedema: role of high-dose melphalan with autologous stem cell transplantation. Blood 2006; 107: 463–466.

    Article  CAS  Google Scholar 

  15. Charlson ME, Pompei P, Ales KL, MacKenzie CR . A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373–383.

    Article  CAS  Google Scholar 

  16. Charlson M, Szatrowski TP, Peterson J, Gold J . Validation of a combined comorbidity index. J Clin Epidemiol 1994; 47: 1245–1251.

    Article  CAS  Google Scholar 

  17. Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005; 106: 2912–2919.

    Article  CAS  Google Scholar 

  18. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23: 3412–3420.

    Article  Google Scholar 

  19. Dimopoulos MA, Weber D, Kantarjian H, Delasalle KB, Alexanian R . HyperCVAD for VAD-resistant multiple myeloma. Am J Hematol 1996; 52: 77–81.

    Article  CAS  Google Scholar 

  20. Kusnierz-Glaz CR, Schlegel PG, Wong RM, Schriber JR, Chao NJ, Amylon MD et al. Influence of age on the outcome of 500 autologous bone marrow transplant procedures for hematologic malignancies. J Clin Oncol 1997; 15: 18–25.

    Article  CAS  Google Scholar 

  21. Powles R, Raje N, Milan S, Millar B, Shepherd V, Mehta J et al. Outcome assessment of a population-based group of 195 unselected myeloma patients under 70 years of age offered intensive treatment. Bone Marrow Transplant 1997; 20: 435–443.

    Article  CAS  Google Scholar 

  22. Dumontet C, Ketterer N, Espinouse D, Neidhardt EM, Moullet I, Thieblemont C et al. Reduced progression-free survival in elderly patients receiving intensification with autologous peripheral blood stem cell reinfusion for multiple myeloma. Bone Marrow Transplant 1998; 21: 1037–1041.

    Article  CAS  Google Scholar 

  23. Palumbo A, Triolo S, Argentino C, Bringhen S, Dominietto A, Rus C et al. Dose-intensive melphalan with stem cell support (MEL100) is superior to standard treatment in elderly myeloma patients. Blood 1999; 94: 1248–1253.

    CAS  PubMed  Google Scholar 

  24. Sirohi B, Powles R, Treleaven J, Mainwaring P, Kulkarni S, Pandha H et al. The role of autologous transplantation in patients with multiple myeloma aged 65 years and over. Bone Marrow Transplant 2000; 25: 533–539.

    Article  CAS  Google Scholar 

  25. Anagnostopoulos A, Aleman A, Ayers G, Donato M, Champlin R, Weber D et al. Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma. Cancer 2004; 100: 2607–2612.

    Article  CAS  Google Scholar 

  26. Facon T, Mary J, Harousseau J, Huguet F, Berthou C, Grosbois B et al. Superiority of melphalan–prednisone (MP) + thalidomide (THAL) over MP and autologous stem cell transplantation in the treatment of newly diagnosed elderly patients with multiple myeloma. 2006 ASCO Annual Meeting Proceedings. 2006; 1: 18S.

  27. Fermand JP, Ravaud P, Chevret S, Divine M, Leblond V, Belanger C et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood 1998; 92: 3131–3136.

    CAS  PubMed  Google Scholar 

  28. San Miguel JF, Garcia-Sanz R . Prognostic features of multiple myeloma. Best Pract Res Clin Haematol 2005; 18: 569–583.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Blood and Marrow Transplantation, University of Texas MD Anderson Cancer Center, Houston, TX, USA

    M H Qazilbash, R M Saliba, C Hosing, F Mendoza, S R Qureshi, T Flosser, D R Couriel, M De Lima, P Kebriaei, U Popat, A M Alousi, R E Champlin & S A Giralt

  2. Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA

    D M Weber & M Wang

Authors
  1. M H Qazilbash
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R M Saliba
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C Hosing
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. F Mendoza
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S R Qureshi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. D M Weber
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. T Flosser
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. D R Couriel
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. M De Lima
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. P Kebriaei
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. U Popat
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. A M Alousi
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. R E Champlin
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. S A Giralt
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M H Qazilbash.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Qazilbash, M., Saliba, R., Hosing, C. et al. Autologous stem cell transplantation is safe and feasible in elderly patients with multiple myeloma. Bone Marrow Transplant 39, 279–283 (2007). https://doi.org/10.1038/sj.bmt.1705580

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1705580

Keywords

This article is cited by

Search

Advanced search

Quick links